The group 2 metabotropic glutamate receptor agonist LY379268 rescues neuronal, neurochemical and motor abnormalities in R6/2 Huntington's disease mice

Neurobiology of Disease

Volumn 47, Issue 1, 2012, Pages 75-91

  Reiner, A ^a   Lafferty, D C ^a   Wang, H B ^a   Del Mar, N ^a   Deng, Y P ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

Akinesia; Huntington's disease; MGluR2 3; Striatum; Therapy

Indexed keywords

4 AMINO 2 OXABICYCLO[3.1.0]HEXANE 4,6 DICARBOXYLIC ACID;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN CORTEX; CAG REPEAT; CONTROLLED STUDY; CORPUS STRIATUM; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG BRAIN LEVEL; DRUG DOSE INCREASE; DRUG MECHANISM; FEMALE; GENE SEQUENCE; HISTOPATHOLOGY; HUNTINGTON CHOREA; LIFESPAN; LOCOMOTION; MALE; MOTOR ACTIVITY; MOTOR DYSFUNCTION; MOUSE; NEUROPROTECTION; NONHUMAN; NUCLEOTIDE SEQUENCE; OPEN FIELD TEST; PHENOTYPE; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; ROTAROD TEST; SIGNAL TRANSDUCTION; SURVIVAL RATE; TRANQUILIZING ACTIVITY;

AMINO ACIDS; ANIMALS; BICYCLO COMPOUNDS, HETEROCYCLIC; CEREBRAL CORTEX; COHORT STUDIES; DISEASE MODELS, ANIMAL; FEMALE; HUNTINGTON DISEASE; MALE; MICE; MICE, TRANSGENIC; MOTOR ACTIVITY; NEOSTRIATUM; NEURONS; RECEPTORS, METABOTROPIC GLUTAMATE; SEX FACTORS;

EID: 84861228589     PISSN: 09699961     EISSN: 1095953X     Source Type: Journal    
DOI: 10.1016/j.nbd.2012.03.025     Document Type: Article

References (174)

1. Albin R.L., Reiner A., Anderson K.D., Dure L.St, Handelin B., Balfour R., Whetsell W.O., Penney J.B., Young A.B. Preferential loss of striato-external pallidal projection neurons in presymptomatic Huntington's disease. Ann. Neurol. 1992, 31:425-430.
2. Alexander G.E., Crutcher M.D. Functional architecture of basal ganglia circuits: neural substrates of parallel processing. Trends Neurosci. 1990, 13:266-271.
3. Allen Brain Atlas http://mouse.brain-map.org/welcome.do.
4. Altar C.A., Cai N., Bliven T., Juhasz M., Conner J.M., Acheson A.L., Lindsay R.M., Wiegand S.J. Anterograde transport of brain-derived neurotrophic factor and its role in the brain. Nature 1997, 389:856-860.
5. Andre V.M., Cepeda C., Venegas A., Gomez Y., Levine M.S. Altered cortical glutamate receptor function in the r6/2 model of Huntington's disease. J. Neurophysiol. 2006, 95:2108-2119.
6. Arning L., Saft C., Wieczorek S., Andrich J., Kraus P.H., Epplen J.T. NR2A and NR2B receptor gene variations modify age at onset in Huntington disease in a sex-specific manner. Hum. Genet. 2007, 122:175-182.
7. Arrasate M., Mitra S., Schweitzer E.S., Segal M.R., Finkbeiner S. Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death. Nature 2004, 431:805-810.
8. Arzberger T., Krampfl K., Leimgruber S., Weindl A. Changes of NMDA receptor subunit (NR1, NR2B) and glutamate transporter (GLT1) mRNA expression in Huntington's disease-an in situ hybridization study. J. Neuropathol. Exp. Neurol. 1997, 56:440-454.
9. Askanas V., Serdaroglu P., Engel W.K., Alvarez R.B. Immunocytochemical localization of ubiquitin in inclusion body myositis allows its light-microscopic distinction from polymyositis. Neurology 1992, 42:460-461.
10. Baquet Z.C., Gorski J.A., Jones K.R. Early striatal dendrite deficits followed by neuron loss with advanced age in the absence of anterograde cortical brain-derived neurotrophic factor. J. Neurosci. 2004, 24:4250-4258.
11. Battaglia G., Monn J.A., Schoepp D.D. In vivo inhibition of veratridine-evoked release of striatal excitatory amino acids by the group II metabotropic glutamate receptor agonist LY354740 in rats. Neurosci. Lett. 1997, 229:161-164.
12. Battaglia G., Cannella M., Riozzi B., Orobello S., Maat-Schieman M.L., Aronica E., Busceti C.L., Ciarmiello A., Alberti S., Amico E., Sassone J., Sipione S., Bruno V., Frati L., Nicoletti F., Squitieri F. Early defect of transforming growth factor β1 formation in Huntington's disease. J. Cell. Mol. Med. 2011, 15:555-571.
13. Beal M.F., Ferrante R.J., Swartz K.J., Kowall N.W. Chronic quinolinic acid lesions in rats closely resemble Huntington's disease. J. Neurosci. 1991, 11:1649-1659.
14. Behrens P.F., Franz P., Woodman B., Lindenberg K.S., Landwehrmeyer G.B. Impaired glutamate transport and glutamate-glutamine cycling: downstream effects of the Huntington mutation. Brain 2002, 125:1908-1922.
15. Bluhmke I. NeuN: a useful neuronal marker for diagnostic histopathology. J. Histochem. Cytochem. 1996, 44:1167-1171.
16. Bolivar V.J., Manley K., Messer A. Exploratory activity and fear conditioning abnormalities develop early in R6/2 Huntington's disease transgenic mice. Behav. Neurosci. 2003, 117:1233-1242.
17. Bond A., Ragumoorthy N., Monn J.A., Hick C.A., Ward M.A., Lodge D., O'Neill M.J. LY379268, a potent and selective group II metabotropic glutamate receptor agonist, is neuroprotective in gerbil global, but not focal cerebral ischemia. Neurosci. Lett. 1999, 273:191-194.
18. Bond A., Jones N.M., Hicks C.A., Whiffin G.M., Ward M.A., O'Neill M.F., Kingston A.E., Monn J.A., Ornstein P.L., Schoepp D.D., Lodge D., O'Neill M.J. Neuroprotective effects of LY379268, a selective mGluR2/3 receptor agonist: investigations into possible mechanism of action in vivo. J. Pharmacol. Exp. Ther. 2000, 294:800-809.
19. Bouras C., Vallet P.G., Hof P.R. Asymmetric increase in substance P immunoreactivity in the rat and guinea pig substantia nigra after unilateral neocortical ablation. Neurosci. Lett. 1991, 133:53-56.
20. Bruno V., Sureda F.X., Storto M., Casabona G., Caruso A., Knopfel T., Kuhn R., Nicoletti F. The neuroprotective activity of group-II metabotropic glutamate receptors requires new protein synthesis and involves a glial-neuronal signaling. J. Neurosci. 1997, 17:1891-1897.
21. Bruno V., Battaglia G., Casabona G., Copani A., Caciagli F., Nicoletti F. Neuroprotection by glial metabotropic glutamate receptors is mediated by transforming growth factor-beta. J. Neurosci. 1998, 18:9594-9600.
22. Cai Z., Xiao F., Fratkin J.D., Rhodes P.G. Protection of neonatal rat brain from hypoxic-ischemic injury by LY379268, a Group II metabotropic glutamate receptor agonist. Neuroreport 1999, 10:3927-3931.
23. Canals J.M., Pineda J.R., Torres-Peraza J.F., Bosch M., Martin-Ibanez R., Muñoz M.T., Mengod G., Ernfors P., Alberch J. Brain-derived neurotrophic factor regulates the onset and severity of motor dysfunction associated with enkephalinergic neuronal degeneration in Huntington's disease. J. Neurosci. 2004, 24:7727-7739.
24. Carter R.J., Hunt M.J., Morton A.J. Environmental stimulation increases survival in mice transgenic for exon 1 of the Huntington's disease gene. Mov. Disord. 2000, 15:925-937.
25. Cepeda C., Ariano M.A., Calvert C.R., Flores-Hernandez J., Chandler S.H., Leavitt B.R., Hayden M.R., Levine M.S. NMDA receptor function in mouse models of Huntington disease. J. Neurosci. Res. 2001, 66:525-539.
26. Cepeda C., Wu N., Andre V.M., Cummings D.M., Levine M.S. The corticostriatal pathway in Huntington's disease. Prog. Neurobiol. 2007, 81:253-271.
27. Cha J.H., Kosinski C.M., Kerner J.A., Alsdorf S.A., Mangiarini L., Penney J.B., Davies S.W., Bates G.P., Young A.B. Altered brain neurotransmitter receptors in transgenic mice expressing a portion of an abnormal human Huntington disease gene. Proc. Natl. Acad. Sci. U. S. A. 1999, 95:6480-6485.
28. Charpier S., Deniau J.M. In vivo activity-dependent plasticity at cortico-striatal connections: evidence for physiological long-term potentiation. Proc. Natl. Acad. Sci. U. S. A. 1997, 94:7036-7040.
29. Conn P.J., Pin J.P. Pharmacology and functions of metabotropic glutamate receptors. Annu. Rev. Pharmacol. Toxicol. 1997, 37:205-237.
30. Copani A., Bruno V.M., Barresi V., Battaglia G., Condorelli D.F., Nicoletti F. Activation of metabotropic glutamate receptors prevents neuronal apoptosis in culture. J. Neurochem. 1995, 64:101-108.
31. Corti C., Battaglia G., Molinaro G., Riozzi B., Pittaluga A., Corsi M., Mugnaini M., Nicoletti F., Bruno V. The use of knock-out mice unravels distinct roles for mGlu2 and mGlu3 metabotropic glutamate receptors in mechanisms of neurodegeneration/neuroprotection. J. Neurosci. 2007, 27:8297-8308.
32. Cowan C.M., Raymond L.A. Selective neuronal degeneration in Huntington's disease. Curr. Top. Dev. Biol. 2006, 75:25-71.
33. Cozzi A., Attucci S., Peruginelli F., Marinozzi M., Luneia R., Pellicciari R., Moroni F. Type 2 metabotropic glutamate (mGlu) receptors tonically inhibit transmitter release in rat caudate nucleus: in vivo studies with (2S,1'S,2'S,3'R)-2-(2'-carboxy-3'-phenylcyclopropyl)glycine, a new potent and selective antagonist. Eur. J. Neurosci. 1997, 9:1350-1355.
34. Crook Z.R., Housman D. Huntington's disease: can mice lead the way to treatment?. Neuron 2011, 69:423-435.
35. Cui L., Jeong H., Borovecki F., Parkhurst C.N., Tanese N., Krainc D. Transcriptional repression of PGC-1alpha by mutant huntingtin leads to mitochondrial dysfunction and neurodegeneration. Cell 2006, 127:59-69.
36. Czlonkowska A., Ciesielska A., Gromadzka G., Kurkowska-Jastrzebska I. Estrogen and cytokines production - the possible cause of gender differences in neurological diseases. Curr. Pharm. Des. 2005, 11:1017-1030.
37. Davies C.H., Clarke V.R., Jane D.E., Collingridge G.L. Pharmacology of postsynaptic metabotropic glutamate receptors in rat hippocampal CA1 pyramidal neurones. Br. J. Pharmacol. 1995, 116:1859-1869.
38. Davies S.W., Turmaine M., Cozens B.A., DiFiglia M., Sharp A.H., Ross C.A., Scherzinger E., Wanker E.E., Mangiarini L., Bates G.P. Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the Huntington's disease mutation. Cell 1997, 90:537-548.
39. Decressac M., Wright B., Tyers P., Gaillard A., Barker R.A. Neuropeptide Y modifies the disease course in the R6/2 transgenic model of Huntington's disease. Exp. Neurol. 2010, 226:24-32.
40. DeLong M.R. Primate models of movement disorders of basal ganglia origin. Trends Neurosci. 1990, 13:281-285.
41. Deng Y.P., Penney J.B., Young A.B., Albin R.L., Anderson K.D., Reiner A. Differential loss of striatal projection neurons in Huntington's disease: a quantitative immunohistochemical study. J. Chem. Neuroanat. 2004, 27:143-164.
42. Di Liberto V., Bonomo A., Frinchi M., Belluardo N., Mudo G. Group II metabotropic glutamate receptor activation by agonist LY379268 treatment increases the expression of brain derived neurotrophic factor in the mouse brain. Neuroscience 2010, 165:863-873.
43. DiFiglia M., Sapp E., Chase K.O., Davies S.W., Bates G.P., Vonsattel J.P., Aronin N. Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science 1997, 277:1990-1993.
44. D'Onofrio M., Cuomo L., Battaglia G., Ngomba R.T., Storto M., Kingston A.E., Orzi F., De Blasi A., Di Iorio P., Nicoletti F., Bruno V. Neuroprotection mediated by glial group-II metabotropic glutamate receptors requires the activation of the MAP kinase and the phosphatidylinositol-3-kinase pathways. J. Neurochem. 2001, 78:435-445.
45. Dorner J.L., Miller B.R., Barton S.J., Brock T.J., Rebec G.V. Sex differences in behavior and striatal ascorbate release in the 140 CAG knock-in mouse model of Huntington's disease. Behav. Brain Res. 2007, 178:90-97.
46. Dragatsis I., Levine M., Zeitlin S. Inactivation of the mouse Huntington's disease gene in the brain and testis results in progressive neurodegeneration and sterility. Nat. Genet. 2000, 26:300-306.
47. Dragatsis I., Goldowitz D., Del Mar N., Deng Y.P., Meade C.A., Liu L., Sun Z., Dietrich P., Yue J., Reiner A. CAG repeat lengths ≥335 attenuate the phenotype in the R6/2 Huntington's disease transgenic mouse. Neurobiol. Dis. 2009, 33:315-330.
48. Drai D., Golani I. SEE: a tool for the visualization and analysis of rodent exploratory behavior. Neurosci. Biobehav. Rev. 2001, 25:409-426.
49. Drai D., Benjamini Y., Golani I. Statistical discrimination of natural modes of motion in rat exploratory behavior. J. Neurosci. Methods 2000, 96:119-131.
50. Fan M.M., Raymond L.A. N-methyl-d-aspartate (NMDA) receptor function and excitotoxicity in Huntington's disease. Prog. Neurobiol. 2007, 81:272-293.
51. Fan M.M., Fernandes H.B., Zhang L.Y., Hayden M.R., Raymond L.A. Altered NMDA receptor trafficking in a yeast artificial chromosome transgenic mouse model of Huntington's disease. J. Neurosci. 2007, 27:3768-3779.
52. Ferrante R.J., Kubilus J.K., Lee J., Ryu H., Beesen A., Zucker B., Smith K., Kowall N.W., Ratan R.R., Luthi-Carter R., Hersch S.M. Histone deacetylase inhibition by sodium butyrate chemotherapy ameliorates the neurodegenerative phenotype in Huntington's disease mice. J. Neurosci. 2003, 23:9418-9427.
53. Ferrante R.J., Ryu H., Kubilus J.K., D'Mello S., Sugars K.L., Lee J., Lu P., Smith K., Browne S., Beal M.F., Kristal B.S., Stavrovskaya I.G., Hewett S., Rubinsztein D.C., Langley B., Ratan R.R. Chemotherapy for the brain: the antitumor antibiotic mithramycin prolongs survival in a mouse model of Huntington's disease. J. Neurosci. 2004, 24:10335-10342.
54. Figueredo-Cardenas G., Anderson K.D., Chen Q., Veeman C.L., Reiner A. Relative survival of striatal projection neurons and interneurons after intrastriatal injection of quinolinic acid in rats. Exp. Neurol. 1994, 129:37-56.
55. Gauthier L.R., Charrin B.C., Borrell-Pages M., Dompierre J.P., Rangone H., Cordelières F.P., De Mey J., MacDonald M.E., Lessmann V., Humbert S., Saudou F. Huntingtin controls neurotrophic support and survival of neurons by enhancing BDNF vesicular transport along microtubules. Cell 2004, 118:127-138.
56. Gharami K., Xie Y., An J.J., Tonegawa S., Xu B. Brain-derived neurotrophic factor over-expression in the forebrain ameliorates Huntington's disease phenotypes in mice. J. Neurochem. 2008, 105:369-379.
57. Gil J.M., Rego A.C. The R6 lines of transgenic mice: a model for screening new therapies for Huntington's disease. Brain Res. Rev. 2009, 59:410-431.
58. Giralt A., Carretón O., Lao-Peregrin C., Eduardo D., Martín E.D., Alberch J. Conditional BDNF release under pathological conditions improves Huntington's disease pathology by delaying neuronal dysfunction. Mol. Neurodegener. 2011, 6:71-86.
59. Glass M., Dragunow M., Faull R.L.M. The pattern of neurodegeneration in Huntington's disease: a comparative study of cannabinoid, dopamine, adenosine and GABAA receptor alterations in the human basal ganglia in Huntington's disease. Neuroscience 2000, 97:505-519.
60. Gorski J.A., Zeiler S.R., Tamowski S., Jones K.R. Brain-derived neurotrophic factor is required for the maintenance of cortical dendrites. J. Neurosci. 2003, 23:6856-6865.
61. Graham R.K., Deng Y., Slow E.J., Haigh B., Bissada N., Lu G., Pearson J., Shehadeh J., Bertram L., Murphy Z., Warby S.C., Doty C.N., Roy S., Wellington C.L., Leavitt B.R., Raymond L.A., Nicholson D.W., Hayden M.R. Cleavage at the caspase-6 site is required for neuronal dysfunction and degeneration due to mutant huntingtin. Cell 2006, 125:1179-1191.
62. Graham R.K., Pouladi M.A., Joshi P., Lu G., Deng Y., Wu N.P., Figueroa B.E., Metzler M., Andre V.M., Slow E.J., Raymond L., Friedlander R., Levine M.S., Leavitt B.R., Hayden M.R. Differential susceptibility to excitotoxic stress in YAC128 mouse models of Huntington disease between initiation and progression of disease. J. Neurosci. 2009, 29:2193-2204.
63. Gray M., Shirasaki D.I., Cepeda C., Andre V.M., Wilburn B., Lu X.H., Tao J., Yamazaki I., Li S.H., Yi S.E., Li X.J., Levine M.S., Yang X.W. Full-length human mutant huntingtin with a stable polyglutamine repeat can elicit progressive and selective neuropathogenesis in BACHD mice. J. Neurosci. 2008, 28:6182-6195.
64. Hannan A.J. Molecular mediators, environmental modulators and experience-dependent synaptic dysfunction in Huntington's disease. Acta Biochim. Pol. 2004, 51:415-430.
65. Hansson O., Peterson A., Leist M., Nicotera P., Castilho R.F., Brundin P. Transgenic mice expressing a Huntington's disease mutation are resistant to quinolinic acid-induced striatal excitotoxicity. Proc. Natl. Acad. Sci. U. S. A. 1999, 96:8727-8732.
66. Hansson O., Guatteo E., Mercuri N.B., Bernardi G., Li X.J., Castilho R.F., Brundin P. Resistance to NMDA toxicity correlates with appearance of nuclear inclusions, behavioural deficits and changes in calcium homeostasis in mice transgenic for exon 1 of the Huntington gene. Eur. J. Neurosci. 2001, 14:1492-1504.
67. Hardingham G.E., Fukunaga Y., Bading H. Extrasynaptic NMDARs oppose synaptic NMDARs by triggering CREB shut-off and cell death pathways. Nat. Neurosci. 2002, 5:405-414.
68. Hassel B., Tessler S., Faull R.L., Emson P.C. Glutamate uptake is reduced in prefrontal cortex in Huntington's disease. Neurochem. Res. 2008, 33:232-237.
69. Hathorn T., Snyder-Keller A., Messer A. Nicotinamide improves motor deficits and upregulates PGC-1a and BDNF gene expression in a mouse model of Huntington's disease. Neurobiol. Dis. 2011, 41:43-50.
70. Hedreen J.C., Peyser C.E., Folstein S.E., Ross C.A. Neuronal loss in layers V and VI of cerebral cortex in Huntington's disease. Neurosci. Lett. 1991, 133:257-261.
71. Heng M.Y., Detloff P.J., Wang P.L., Tsien J.Z., Albin R.L. In vivo evidence for NMDA receptor-mediated excitotoxicity in a murine genetic model of Huntington disease. J. Neurosci. 2009, 29:3200-3205.
72. Hickey M.A., Kosmalska A., Enayati J., Cohen R., Zeitlin S., Levine M.S., Chesselet M.F. Extensive early motor and non-motor behavioral deficits are followed by striatal neuronal loss in knock-in Huntington's disease mice. Neuroscience 2008, 157:280-295.
73. Hockly E., Cordery P.M., Woodman B., Mahal A., van Dellen A., Blakemore C., Lewis C.M., Hannan A.J., Bates G.P. Environmental enrichment slows disease progression in R6/2 Huntington's disease mice. Ann. Neurol. 2002, 51:235-242.
74. Hockly E., Richon V.M., Woodman B., Smith D.L., Zhou X., Rosa E., Sathasivam K., Ghazi-Noori S., Mahal A., Lowden P.A., Steffan J.S., Marsh J.L., Thompson L.M., Lewis C.M., Marks P.A., Bates G.P. Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's disease. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:2041-2046.
75. Hockly E., Woodman B., Mahal A., Lewis C.M., Bates G. Standardization and statistical approaches to therapeutic trials in the R6/2 mouse. Brain Res. Bull. 2003, 61:469-479.
76. Imre G. The preclinical properties of a novel group II metabotropic glutamate receptor agonist LY379268. CNS Drug Rev. 2007, 13:444-464.
77. Johnson C.D., Davidson B.L. Huntington's disease: progress toward effective disease-modifying treatments and a cure. Hum. Mol. Genet. 2010, 9(R1):R98-R102.
78. Joshi P.R., Wu N.P., Andre V.M., Cummings D.M., Cepeda C., Joyce J.A., Carroll J.B., Leavitt B.R., Hayden M.R., Levine M.S., Bamford N.S. Age-dependent alterations of corticostriatal activity in the YAC128 mouse model of Huntington disease. J. Neurosci. 2009, 29:2414-2427.
79. Kafkafi N., Mayo C., Drai D., Golani I., Elmer G. Natural segmentation of the locomotor behavior of drug-induced rats in a photobeam cage. J. Neurosci. Methods 2001, 109:111-121.
80. Kafkafi N., Lipkind D., Benjamini Y., Mayo C.L., Elmer G.I., Golani I. SEE locomotor behavior test discriminates C57BL/6J and DBA/2J mouse inbred strains across laboratories and protocol conditions. Behav. Neurosci. 2003, 117:464-477.
81. Kehoe P., Krawczak M., Harper P.S., Owen M.J., Jones A.L. Age of onset in Huntington disease: sex specific influence of apolipoprotein E genotype and normal CAG repeat length. J. Med. Genet. 1999, 36:108-111.
82. Kenchappa R.S., Diwakar L., Annepu J., Ravindranath V. Estrogen and neuroprotection: higher constitutive expression of glutaredoxin in female mice offers protection against MPTP-mediated neurodegeneration. FASEB J. 2004, 18:1102-1104.
83. Kew J.N., Ducarre J.M., Pflimlin M.C., Mutel V., Kemp J.A. Activity-dependent presynaptic autoinhibition by group II metabotropic glutamate receptors at the perforant path inputs to the dentate gyrus and CA1. Neuropharmacology 2001, 40:20-27.
84. Kim K.K., Adelstein R.S., Kawamoto S. Identification of neuronal nuclei (NeuN) as Fox-3, a new member of the Fox-1 gene family of splicing factors. J. Biol. Chem. 2009, 284:31052-31061.
85. King A.E., Liu X.H. Dual action of metabotropic glutamate receptor agonists on neuronal excitability and synaptic transmission in spinal ventral horn neurons in vitro. Neuropharmacology 1996, 35:1673-1680.
86. Kingston A.E., O'Neill M.J., Lam A., Bales K.R., Monn J.A., Schoepp D.D. Neuroprotection by metabotropic glutamate receptor agonists: LY2354740, LY379268 and LY389795. Eur. J. Pharmacol. 1999, 377:155-165.
87. Kravitz A.V., Freeze B.S., Parker P.R.L., Kay K., Thwin M.T., Deisseroth K., Kreitzer A.C. Regulation of Parkinsonian motor behaviours by optogenetic control of basal ganglia circuitry. Nature 2010, 466:624-629.
88. Kuhn A., Goldstein D.R., Hodges A., Strand A.D., Sengstag T., Kooperberg C., Becanovic K., Pouladi M.A., Sathasivam K., Cha J.H., Hannan A.J., Hayden M.R., Leavitt B.R., Dunnett S.B., Ferrante R.J., Albin R., Shelbourne P., Delorenzi M., Augood S.J., Faull R.L., Olson J.M., Bates G.P., Jones L., Luthi-Carter R. Mutant huntingtin's effects on striatal gene expression in mice recapitulate changes observed in human Huntington's disease brain and do not differ with mutant huntingtin length or wild-type huntingtin dosage. Hum. Mol. Genet. 2007, 16:1845-1861.
89. Lande R. Quantitative genetic analysis of multivariate evolution, applied to brain: body size allometry. Evolution 1979, 30:402-416.
90. Lei W., Jiao Y., Del Mar N., Reiner A. Evidence for differential cortical input to direct pathway versus indirect pathway striatal projection neurons in rats. J. Neurosci. 2004, 24:8289-8299.
91. Lessmann V., Gottmann K., Malcangio M. Neurotrophin secretion: current facts and future prospects. Prog. Neurobiol. 2003, 69:341-374.
92. Leveille F., El Gaamouch F., Gouix E., Lecocq M., Lobner D., Nicole O., Buisson A. Neuronal viability is controlled by a functional relation between synaptic and extrasynaptic NMDA receptors. FASEB J. 2008, 22:4258-4271.
93. Li S.H., Li X.J. Huntingtin and its role in neuronal degeneration. Neuroscientist 2004, 10:467-475.
94. Li H., Li S.H., Cheng A.L., Mangiarini L., Bates G.P., Li X.J. Ultrastructural localization and progressive formation of neuropil aggregates in Huntington's disease transgenic mice. Hum. Mol. Genet. 1999, 8:1227-1236.
95. Li L., Murphy T.H., Hayden M.R., Raymond L.A. Enhanced striatal NR2B-containing N-methyl-d-aspartate receptor-mediated synaptic currents in a mouse model of Huntington disease. J. Neurophysiol. 2004, 92:2738-2746.
96. Lievens J.C., Bernal F., Forni C., Mahy N., Kerkerian-Le Goff L. Characterization of striatal lesions produced by glutamate uptake alteration: cell death, reactive gliosis, and changes in GLT1 and GADD45 mRNA expression. Glia 2000, 29:222-232.
97. Lievens J.C., Woodman B., Mahal A., Spasic-Boscovic O., Samuel D., Kerkerian-Le Goff L., Bates G.P. Impaired glutamate uptake in the R6 Huntington's disease transgenic mice. Neurobiol. Dis. 2001, 8:807-821.
98. Lipkind D., Sakov A., Kafkafi N., Elmer G.I., Benjamini Y., Golani I. New replicable anxiety-related measures of wall vs center behavior of mice in the open field. J. Appl. Physiol. 2004, 97:347-359.
99. Lisman J.E. Bursts as a unit of neural information: making unreliable synapses reliable. Trends Neurosci. 1997, 20:38-43.
100. Liu X.B., Munoz A., Jones E.G. Changes in subcellular localization of metabotropic glutamate receptor subtypes during postnatal development of mouse thalamus. J. Comp. Neurol. 1998, 395:450-465.
101. Lorrain D.S., Baccei C.S., Bristow L.J., Anderson J.J., Varney M.A. Effects of ketamine and N-methyl-d-aspartate on glutamate and dopamine release in the rat prefrontal cortex: modulation by a group II selective metabotropic glutamate receptor agonist LY379268. Neuroscience 2003, 117:697-706.
102. Lovinger D.M., McCool B.A. Metabotropic glutamate receptor-mediated presynaptic depression at corticostriatal synapses involves mGLuR2 or 3. J. Neurophysiol. 1995, 73:1076-1083.
103. Luthi-Carter R., Strand A., Peters N.L., Solano S.M., Hollingsworth Z.R., Menon A.S., Frey A.S., Spektor B.S., Penney E.B., Schilling G., Ross C.A., Borchelt D.R., Tapscott S.J., Young A.B., Cha J.H., Olson J.M. Decreased expression of striatal signaling genes in a mouse model of Huntington's disease. Hum. Mol. Genet. 2000, 9:1259-1271.
104. Ma T.C., Buescher J.L., Oatis B., Funk J.A., Nash A.J., Carrier R.L., Hoyt K.R. Metformin therapy in a transgenic mouse model of Huntington's disease. Neurosci. Lett. 2007, 411:98-103.
105. Mangiarini L., Sathasivam K., Seller M., Cozens B., Harper A., Hetherington C., Lawton M., Trottier Y., Lehrach H., Davies S.W., Bates G.P. Exon 1 of the Huntington's disease gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 1996, 87:493-506.
106. McCombe P.A., Henderson R.D. Effects of gender in amyotrophic lateral sclerosis. Gend. Med. 2010, 7:557-570.
107. McCool B.A., Pin J.P., Brust P.F., Harpold M.M., Lovinger D.M. Functional coupling of rat group II metabotropic glutamate receptors to an omega-conotoxin GVIA-sensitive calcium channel in human embryonic kidney 293 cells. Mol. Pharmacol. 1996, 50:912-922.
108. Meade C.A., Figueredo-Cardenas G., Fusco F.R., Nowak T.S., Pulsinelli W., Reiner A. Transient global ischemia in rats yields striatal projection neuron and interneuron loss resembling that in Huntington's disease. Exp. Neurol. 2000, 166:307-323.
109. Meade C.A., Deng Y.P., Fusco F., Del Mar N., Hersch S., Goldowitz D., Reiner A. Localization of neuronal intranuclear inclusions (NIIs) in the striatum and cortex of the Bates R6/2 transgenic mouse. J. Comp. Neurol. 2002, 449:241-269.
110. Menalled L., Zanjani H., MacKenzie L., Koppel A., Carpenter E., Zeitlin S., Chesselet M.F. Decrease in striatal enkephalin mRNA in mouse models of Huntington's disease. Exp. Neurol. 2000, 162:328-342.
111. Menalled L., El-Khodor B.F., Patry M., Suárez-Fariñas M., Orenstein S.J., Zahasky B., Leahy C., Wheeler V., Yang X.W., MacDonald M., Morton A.J., Bates G., Leeds J., Park L., Howland D., Signer E., Tobin A., Brunner D. Systematic behavioral evaluation of Huntington's disease transgenic and knock-in mouse models. Neurobiol. Dis. 2009, 35:319-336.
112. Miller B.R., Walker A.G., Shah A.S., Barton S.J., Rebec G.V. Dysregulated information processing by medium spiny neurons in striatum of freely behaving mouse models of Huntington's disease. J. Neurophysiol. 2008, 100:2205-2216.
113. Milnerwood A.J., Raymond L.A. Corticostriatal synaptic function in mouse models of Huntington's disease: early effects of huntingtin repeat length and protein load. J. Physiol. 2007, 585:817-831.
114. Milnerwood A.J., Cummings D.M., Dallerac G.M., Brown J.Y., Vatsavayai S.C., Hirst M.C., Rezaie P., Murphy K.P. Early development of aberrant synaptic plasticity in a mouse model of Huntington's disease. Hum. Mol. Genet. 2006, 15:1690-1703.
115. Milnerwood A.J., Gladding C.M., Pouladi M.A., Kaufman A.M., Hines R.M., Boyd J.D., Ko R.W.Y., Vasuta O.C., Graham R.K., Hayden M.R., Murphy T.H., Raymond L.A. Early Increase in extrasynaptic NMDA receptor signaling and expression contributes to phenotype onset in Huntington's disease mice. Neuron 2010, 65:178-190.
116. Monn J.A., Valli M.J., Massey S.M., Wright R.A., Salhoff C.R., Johnson B.G., Howe T., Alt C.A., Rhodes G.A., Robey R.L., Griffey K.R., Tizzano J.P., Kallman M.J., Helton D.R., Schoepp D.D. Design, synthesis, and pharmacological characterization of (+)-2-aminobicyclo [3.1.0]hexane-2,6-dicarboxylic acid (LY354740): a potent, selective, and orally active group 2 metabotropic glutamate receptor agonist possessing anticonvulsant and anxiolytic properties. J. Med. Chem. 1997, 40:528-537.
117. Monn J.A., Valli M.J., Massey S.M., Hansen M.M., Kress T.J., Wepsiec J.P., Harkness A.R., Grutsch J.L., Wright R.A., Johnson B.G., Andis S.L., Kingston A.E., Tomlinson R., Lewis R., Griffey K.R., Tizzano J.P., Schoepp D.D. Synthesis, pharmacological characterization, and molecular modeling of heterobicyclic amino acids related to (+)-2-aminobicyclo[3.1.0] hexane-2,6-dicarboxylic acid (LY354740): identification of two new potent, selective, and systemically active agonists for group II metabotropic glutamate receptors. J. Med. Chem. 1999, 42:1027-1040.
118. Monsma F.J., Mahan L.C., McVittie L.D., Gerfen C.R., Sibley D.R. Molecular cloning and expression of a D1 dopamine receptor linked to adenylyl cyclase activation. Proc. Natl. Acad. Sci. U. S. A. 1990, 87:6723-6727.
119. Morton A.J., Glynn D., Leavens W., Zheng Z., Faull R.L.M., Skepper J.N., Wight J.M. Paradoxical delay in the onset of disease caused by super-long CAG repeat expansions in R6/2 mice. Neurobiol. Dis. 2009, 33:331-341.
120. Mullen R.J., Buck C.R., Smith A.M. NeuN, a neuronal specific nuclear protein in vertebrates. Development 1992, 116:201-211.
121. Nakanishi S. Molecular diversity of glutamate receptors and implications for brain function. Science 1992, 258:597-603.
122. Ohishi H., Shigemoto R., Nakanishi S., Mizuno N. Distribution of the mRNA for a metabotropic glutamate receptor (mGluR3) in the rat brain: an in situ hybridization study. J. Comp. Neurol. 1993, 335:252-266.
123. Okamoto S., Pouladi M.A., Talantova M., Yao D., Xia P., Ehrnhoesfer D.E., Zaidi R., Clemente A., Kaul M., Graham R.K., Zhang D., Chen H.S.V., Tong G., Hayden M.R., Lipton S.A. Balance between synaptic versus extrasynaptic NMDA receptor activity influences inclusions and neurotoxicity of mutant huntingtin. Nat. Med. 2009, 15:1407-1413.
124. Patil S.T., Zhang L., Martenyi F., Lowe S.L., Jackson K.A., Andreev B.V., Avedisova A.S., Bardenstein L.M., Gurovich I.Y., Morozova M.A., Mosolov S.N., Neznanov N.G., Reznik A.M., Smulevich A.B., Tochilov V.A., Johnson B.G., Monn J.A., Schoepp D.D. Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial. Nat. Med. 2007, 13:1102-1107.
125. Pekmezovic T., Svetel M., Maric J., Dujmovic-Basuroski I., Dragasevic N., Keckarevic M., Romac S., Kostic V. Survival of Huntington's disease patients in Serbia: longer survival in female patients. Eur. J. Epidemiol. 2007, 22:523-526.
126. Peng Q., Masuda N., Jiang M., Li Q., Zhao M., Ross C.A., Duan W. The antidepressant sertraline improves the phenotype, promotes neurogenesis and increases BDNF levels in the R6/2 Huntington's disease mouse model. Exp. Neurol. 2008, 210:154-163.
127. Peters J., Kalivas P.W. The group II metabotropic glutamate receptor agonist, LY379268, inhibits both cocaine- and food-seeking behavior in rats. Psychopharmacology (Berl) 2006, 186:143-914.
128. Poo M.M. Neurotrophins as synaptic modulators. Nat. Rev. Neurosci. 2001, 2:24-32.
129. Rebec G.V., Barton S.J., Ennis M.D. Dysregulation of ascorbate release in the striatum of behaving mice expressing the Huntington's disease gene. J. Neurosci. 2002, 22:RC202.
130. Rebec G.V., Conroy S.K., Barton S.J. Hyperactive striatal neurons in symptomatic Huntington R6/2 mice: variations with behavioral state and repeated ascorbate treatment. Neuroscience 2006, 137:327-336.
131. Reddy P.H., Williams M., Tagle D.A. Recent advances in understanding the pathogenesis of Huntington's disease. Trends Neurosci. 1999, 22:248-255.
132. Reiner A. The distribution of proenkephalin-derived peptides in the central nervous system of turtle. J. Comp. Neurol. 1987, 259:65-91.
133. Reiner A., Albin R.L., Anderson K.D., D'Amato C.J., Penney J.B., Young A.B. Differential loss of striatal projection neurons in Huntington disease. Proc. Natl. Acad. Sci. U. S. A. 1988, 85:5733-5737.
134. Reiner A., Del Mar N., Deng Y.P., Meade C.A., Sun Z., Goldowitz D. R6/2 neurons with intranuclear inclusions survive for prolonged periods in the brains of chimeric mice. J. Comp. Neurol. 2007, 505:603-737.
135. Reiner A., Hart N.M., Lei W.L., Deng Y.P. Corticostriatal projection neurons - dichotomous types and dichotomous functions. Front. Neuroanat. 2010, 4. article 142. 10.3389/fnana.2010.00142.
136. Ren R.F., Hawver D.B., Kim R.S., Flanders K.C. Transforming growth factor-b protects human hNT cells from degeneration induced by beta-amyloid peptide: involvement of the TGF-b type II receptor. Mol. Brain Res. 1997, 48:315-322.
137. Richfield E.K., Herkenham M. Selective vulnerability in Huntington's disease: preferential loss of cannabinoid receptors in lateral globus pallidus. Ann. Neurol. 1994, 36:577-584.
138. Richfield E.K., O'Brien C.F., Eskin T., Shoulson I. Heterogeneous dopamine receptor changes in early and late Huntington's disease. Neurosci. Lett. 1991, 132:121-126.
139. Richfield E.K., Maguire-Zeiss K.A., Vonkeman H.E., Voorn P. Preferential loss of preproenkephalin versus preprotachykinin neurons from the striatum of Huntington's disease patients. Ann. Neurol. 1995, 38:852-861.
140. Ridler T.W., Calvard S. Picture thresholding using an iterative selection method. IEEE Trans. Syst. Man Cybern. 1978, 8:630-632.
141. Rodríguez-Navarro J.A., Solano R.M., Casarejos M.J., Gomez A., Perucho J., de Yébenes J.G., Mena M.A. Gender differences and estrogen effects in parkin null mice. J. Neurochem. 2008, 106:2143-2157.
142. Roos R.A.C., Vegter-van der Vlis M., Hermans J., Elshove H.M., Moll A.C., van de Kamp J.J.P., Bruyn G.W. Age at onset in Huntington's disease: effect of line of inheritance and patient's sex. J. Med. Genet. 1991, 28:515-519.
143. Ryu H., Lee J., Hagerty S.W., Soh B.Y., McAlpin S.E., Cormier K.A., Smith K.M., Ferrante R.J. ESET/SETDB1 gene expression and histone H3 (K9) trimethylation in Huntington's disease. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:19176-19181.
144. Sapp E., Ge P., Aizawa H., Bird E., Penney J., Young A.B., Vonsattel J.P., DiFiglia M. Evidence for a preferential loss of enkephalin immunoreactivity in the external globus pallidus in low grade Huntington's disease using high resolution image analysis. Neuroscience 1995, 64:397-404.
145. Scanziani M., Salin P.A., Vogt K.E., Malenka R.C., Nicoll R.A. Use-dependent increases in glutamate concentration activate presynaptic metabotropic glutamate receptors. Nature 1997, 385:630-634.
146. Schiefer J., Landwehrmeyer G.B., Luesse H.G., Sprunken A., Puls C., Milkereit A., Milkereit E., Kosinski C.M. Riluzole prolongs survival time and alters nuclear inclusion formation in a transgenic mouse model of Huntington's disease. Mov. Disord. 2002, 17:748-757.
147. Schiefer J., Sprünken A., Puls C., Lüesse H.G., Milkereit A., Milkereit E., Johann V., Kosinski C.M. The metabotropic glutamate receptor 5 antagonist MPEP and the mGluR2 agonist LY379268 modify disease progression in a transgenic mouse model of Huntington's Disease. Brain Res. 2004, 1019:246-254.
148. Schoepp D.D. Unveiling the functions of presynaptic metabotropic glutamate receptors in the central nervous system. J. Pharmacol. Exp. Ther. 2001, 299:12-20.
149. Schoepp D.D., Jane D.E., Monn J.A. Pharmacological agents acting at subtypes of metabotropic glutamate receptors. Neuropharmacology 1999, 38:1431-1476.
150. Shear D.A., Dong J., Gundy C.D., Haik-Creguer K.L., Dunbar G.L. Comparison of intrastriatal injections of quinolinic acid and 3-nitropropionic acid for use in animal models of Huntington's disease. Prog. Neuropsychopharmacol. Biol. Psychiatry 1998, 22:1217-1240.
151. Shehadeh J., Fernandes H.B., Zeron Mullins M.M., Graham R.K., Leavitt B.R., Hayden M.R., Raymond L.A. Striatal neuronal apoptosis is preferentially enhanced by NMDA receptor activation in YAC transgenic mouse model of Huntington disease. Neurobiol. Dis. 2006, 21:392-403.
152. Shin J.Y., Fang Z.H., Yu Z.X., Wang C.E., Li S.H., Li X.J. Expression of mutant huntingtin in glial cells contributes to neuronal excitotoxicity. J. Cell Biol. 2005, 171:1001-1012.
153. Simmons D.A., Mehta R.A., Lauterborn J.C., Gall C.M., Lynch G. Brief ampakine treatments slow the progression of Huntington's disease phenotypes in R6/2 mice. Neurobiol. Dis. 2011, 41:436-444.
154. Slow E.J., Van Raamsdonk J.M., Rogers D., Coleman S.H., Graham R.K., Deng Y., Oh R., Bissada N., Hossain S.M., Yang Y.Z., Li X.J., Simpson E.M., Gutekunst C.A., Leavitt B.R., Hayden M.R. Selective striatal neuronal loss in a YAC128 mouse model of Huntington's disease. Hum. Mol. Genet. 2003, 12:1555-1567.
155. Somers D.L., Beckstead R.M. Striatal preprotachykinin and preproenkephalin mRNA levels and the levels of nigral substance P and pallidal Met5-enkephalin depend on corticostriatal axons that use the excitatory amino acid neurotransmitters aspartate and glutamate: quantitative radioimmunocytochemical and in situ hybridization evidence. Mol. Brain Res. 1990, 8:143-158.
156. Spillantini M.G., Crowther R.A., Jakes R., Hasegawa M., Goedert M. Alpha-synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with Lewy bodies. Proc. Natl. Acad. Sci. U. S. A. 1998, 95:6469-6473.
157. Stack E.C., Kubilus J.K., Smith K., Cormier K., Del Signore S.J., Guelin E., Ryu H., Hersch S.M., Ferrante R.J. Chronology of behavioral symptoms and neuropathological sequelae in R6/2 Huntington's disease transgenic mice. J. Comp. Neurol. 2005, 490:354-370.
158. Stack E.C., Dedeoglu A., Smith K.M., Cormier K., Kubilus J.K., Bogdanov M., Matson W.R., Yang L., Jenkins B.G., Luthi-Carter R., Kowall N.W., Hersch S.M., Beal M.F., Ferrante R.J. Neuroprotective effects of synaptic modulation in Huntington's disease R6/2 mice. J. Neurosci. 2007, 27:12908-12915.
159. Strand A.D., Baquet Z.C., Aragaki A.K., Holmans P., Yang L., Cleren C., Beal M.F., Jones L., Kooperberg C., Olson J.M., Jones K.R. Expression profiling of Huntington's disease models suggests that brain-derived neurotrophic factor depletion plays a major role in striatal degeneration. J. Neurosci. 2007, 27:11758-11768.
160. Subramaniam S., Sixt K.M., Barrow R., Snyder S.H. Rhes, a striatal specific protein, mediates mutant-huntingtin cytotoxicity. Science 2009, 324:1327-1330.
161. Sun Z., Del Mar N., Meade C., Goldowitz D., Reiner A. Differential changes in striatal projection neurons in R6/2 mice transgenic for Huntington's disease. Neurobiol. Dis. 2002, 11:369-385.
162. Tallaksen-Greene S.J., Janiszewska A., Benton K., Lech Ruprecht L., Albin R.L. Lack of efficacy of NMDA receptor-NR2B selective antagonists in the R6/2 model of Huntington disease. Exp. Neurol. 2010, 225:402-407.
163. Tekkok S.B., Goldberg M.P. AMPA/kainate receptor activation mediates hypoxic oligodendrocyte death and axonal injury in cerebral white matter. J. Neurosci. 2001, 21:4237-4248.
164. Testa C.M., Standaert D.G., Young A.B., Penney J.B. Metabotropic glutamate receptor mRNA expression in the basal ganglia of the rat. J. Neurosci. 1994, 14:3005-3008.
165. Van Raamsdonk J.M., Pearson J., Slow E.J., Hossain S.M., Leavitt B.R., Hayden M.R. Cognitive dysfunction precedes neuropathology and motor abnormalities in the YAC128 mouse model of Huntington's disease. J. Neurosci. 2005, 25:4169-4180.
166. Vonsattel J.P., DiFiglia M. Huntington disease. J. Neuropathol. Exp. Neurol. 1998, 57:369-384.
167. Wang H.B., Laverghetta A.V., Foehring R.F., Deng Y.P., Sun Z., Yamamoto K., Lei W.L., Jiao Y., Reiner A. Single-cell RT-PCR, in situ hybridization histochemical, and immunohistochemical studies of substance P and enkephalin co-occurrence in striatal projection neurons in rats. J. Chem. Neuroanat. 2006, 31:178-199.
168. Wolf H.K., Buslei R., Schmidt-Kastner R., Schmidt-Kastner P.K., Pietsch T., Wiestler O.D., Van Raamsdonk J.M., Murphy Z., Slow E.J., Leavitt B.R., Hayden M.R. Selective degeneration and nuclear localization of mutant huntingtin in the YAC128 mouse model of Huntington disease. Hum. Mol. Genet. 2005, 14:3823-3835.
169. Xie Y., Hayden M.R., Xu B. BDNF Overexpression in the forebrain rescues Huntington's disease phenotypes in YAC128 mice. J. Neurosci. 2010, 30:14708-14718.
170. Zhai Y., George C.A., Zhai J., Nisenbaum E.S., Johnson M.P., Nisenbaum L.K. Group II metabotropic glutamate receptor modulation of DOI-induced c-fos mRNA and excitatory responses in the cerebral cortex. Neuropsychopharmacology 2003, 28:45-52.
171. Zhao Y., Dayas C.V., Aujula H., Baptista M.A., Martin-Fardon R., Weiss F. Activation of group II metabotropic glutamate receptors attenuates both stress and cue-induced ethanol-seeking and modulates c-fos expression in the hippocampus and amygdala. J. Neurosci. 2006, 26:9967-9974.
172. Zuccato C., Cattaneo E. Role of brain-derived neurotrophic factor in Huntington's disease. Prog. Neurobiol. 2007, 81:294-330.
173. Zuccato C., Ciammola A., Rigamonti D., Leavitt B.R., Goffredo D., Conti L., MacDonald M.E., Friedlander R.M., Silani V., Hayden M.R., Timmusk T., Sipione S., Cattaneo E. Loss of huntingtin-mediated BDNF gene transcription in HD. Science 2001, 293:493-498.
174. Zwilling D., Huang S.Y., Sathyasaikumar K.V., Notarangelo K.M., Guidetti P., Wu H.Q., Lee J., Truong J., Andrews-Zwilling Y., Hsieh E.W., Louie J.Y., Wu T., Scearce-Levie K., Patrick C., Adame A., Giorgini F., Moussaoui S., Laue G., Rassoulpour A., Flik G., Huang Y., Muchowski J.M., Masliah E., Schwarcz R., Muchowski P.J. Kynurenine 3-monooxygenase inhibition in blood ameliorates neurodegeneration. Cell 2011, 145:863-874.